secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001558370-24-014773
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Q3 net loss $14.0M; Phase 1C vilastobart + atezolizumab shows partial responses in cold tumors
--------------------------------------------------------------------------------

- Cash $61.3M as of Sept 30, 2024; cash runway through Q2 2025.
- Phase 1C: 2 unconfirmed PRs (MSS CRC with liver lesion resolution, ampullary carcinoma); no Grade 4/5 treatment-related AEs.
- RP2D selected: vilastobart 100 mg Q6W + atezolizumab 1200 mg Q3W; Phase 2 enrolling MSS CRC.
- Initial Phase 2 data for vilastobart combo in ~20 MSS CRC patients expected Q4 2024; ~40 total by Q1 2025.
- License revenue $2.3M from Gilead agreement; net loss $14.0M vs $16.7M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024014773/0001558370-24-014773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024014773/xlo-20241107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer